Clinical trials: Simvastatin
- Drug or intervention Simvastatin
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study of LY3526318 in Healthy Male Japanese Participants
This is a study of LY3526318 in healthy male Japanese. The main purposes of this study are to: Assess how safe and well tolerated LY3526318 is when given by mouth. Measure how LY3526318 affects the kidney and the liver.
- Trial name
- NCT05580250
- Testing
- LY3526318, Iohexol, Simvastatin
- Where
- Japan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3502970 in Healthy Participants
The main purposes of this study are to determine: The safety of LY3502970 and any side effects that might be associated with it. How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it.
- Trial name
- NCT03929744
- Testing
- LY3502970, Atorvastatin, Simvastatin
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin
The purpose of this study is to determine whether MGL-3196 alters the pharmacokinetics of rosuvastatin and/or simvastatin in healthy male subjects and female subjects not of child-bearing potential.
- Trial name
- NCT02542969
- Testing
- Simvastatin, Rosuvastatin, MGL-3196
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Healthy
Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin
This is a Phase 1, Open-Label, 3-Period, Single-sequence, Drug-drug Interaction Study in Healthy Subjects to Assess the Effect of Cenicriviroc on the Pharmacokinetics (PK) of HMG-CoA Reductase Inhibitors [Rosuvastatin (ROS)…
- Trial name
- NCT02685462
- Testing
- Rosuvastatin, Atorvastatin, Simvastatin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
Healthy
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers
The purpose of this study is to determine how multiple doses of canagliflozin (JNJ-28431754) affect the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of a single…
- Trial name
- NCT01821027
- Testing
- Simvastatin, Canagliflozin (JNJ-28431754)
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dyslipidemia, Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia.
- Trial name
- NCT01487460
- Testing
- TAP311
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Hyperlipidemia
Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)
This is a single-center, randomized, open-label, 3-period, 3-treatment multiple-dose crossover study designed to assess the interaction between VYTORIN® (Ezetimibe and Simvastatin) and NIASPAN® (Niacin Extended-Release Tablets)…
- Trial name
- NCT00652431
- Testing
- Vytorin + Niaspan, Vytorin, Niaspan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hyperlipidemia
A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet
People who follow a low-carbohydrate diet typically experience a decrease in triglycerides and increase in HDL-C level, but fail to lower their LDL cholesterol (LDL-C). Such patients may require lipid-lowering therapy.
- Trial name
- LOCUST (NCT00566267)
- Testing
- simvastatin 20 mg/ezetimibe
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypertriglyceridemia
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects
The primary objective is to determine the effect of multiple doses of Epanova® (omega fatty acids) on the pharmacokinetics (PK) of multiple 40 mg doses of simvastatin.
- Trial name
- NCT01486433
- Testing
- Simvastatin, acetylsalicylic acid (ASA), omefas
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
The Drug-drug Interaction of SP2086 and Simvastatin
The purpose of the study is to investigate the potential interaction between SP2086 and Simvastatin after the multiple oral doses treatment in healthy adult volunteers.
- Trial name
- NCT02815722
- Testing
- SP2086, Simvastatin
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Human Volunteers
Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics
The purpose of this study is to estimate the effect of multiple oral doses of PF-03882845 on the pharmacokinetics of simvastatin and simvastatin acid in healthy, adult subjects.
- Trial name
- NCT01445860
- Testing
- Simvastatin/PF-03882845
- Where
- Singapore
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Study of Baricitinib and Simvastatin in Healthy Participants
The purposes of this study are to determine the effects of baricitinib on the time it takes to remove simvastatin from the body and to look at how well-tolerated and safe baricitinib is when given alone and in combination with…
- Trial name
- NCT01960140
- Testing
- Baricitinib, Simvastatin
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Drug-drug Interaction
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
A single-center, open-label, Phase 1, drug-drug interaction study to investigate the effect of voclosporin on the pharmacokinetics of simvastatin and simvastatin acid in healthy volunteers.
- Trial name
- Statin-DDI (NCT05306379)
- Testing
- Simvastatin, Voclosporin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Aurinia Pharmaceuticals Inc.
Pulmonary Disease, Chronic Obstructive
A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects
To assess safety of SB-656933 following repeat dosing for 14 days.
- Trial name
- NCT00504439
- Testing
- SB-656933-AAA, Simvastatin
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects
This is a randomized, open-label study to evaluate the effect of a single dose of SSP-004184 on the pharmacokinetics of a single dose of simvastatin in healthy adult subjects.
- Trial name
- NCT01979185
- Testing
- Simvastatin, SSP-004184SS
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Shire
Type 2 Diabetes Mellitus
Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects
To assess the effect of PEX168 doses on the pharmacokinetics of simvastatin(as determined by simvastation acid) in healthy subjects. To assess the safety of single doses of simvastation administered with and without PEX168
- Trial name
- NCT02447601
- Testing
- PEX168, Simvastatin
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Healthy
Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
This phase II, open-label research study was conducted in 129 healthy volunteers. Each subject will be given one initial oral dose of one of 7 FDA-approved medications (probe drugs), followed by a 7 day period where subjects…
- Trial name
- NCT00359281
- Testing
- atorvastatin, simvastatin, ezetimibe
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Sleep Disorders
A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of SB-649868 on the Pharmacokinetics of Simvastatin and Atorvastatin in Healthy Male Volunteers.
The present study will investigate in humans the enzyme inhibition effects of SB-649868 on CYP3A4, using Simvastatin and Atorvastatin as CYP3A4 probe substrates, administered as single doses: alone, and on two different occasions…
- Trial name
- NCT01299597
- Testing
- Atorvastatin, Simvastatin, SB649868
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
Phase A - To assess the effect of simvastatin on the pharmacokinetics (PK) of dapagliflozin and to determine the effect of dapagliflozin on the PK of simvastatin, when simvastatin and dapagliflozin are coadministered in healthy…
- Trial name
- NCT00839683
- Testing
- simvastatin, Dapagliflozin, valsartan
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca